Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial

Journal of Human Hypertension volume 19, pages 277–283 (2005)Cite this article

Abstract

Obesity has been shown to be associated with increased left ventricular mass (LVM) and heart sympathetic activity even in nonhypertensive subjects. These factors are predictors of cardiovascular morbidity and mortality independent of other traditional risk factors. We evaluated the effect of losartan and spironolactone on LVM and heart sympathetic activity in prehypertensive obese subjects. A 16-week blinded randomized trial was performed in middle-aged men selected from a Health Public program. Anthropometric and clinical variables were measured at baseline and after losartan (50 mg/day; n=25) or spironolactone (25 mg/day; n=25) treatment. Heart sympathetic activity was evaluated with 60-min electrocardiograph monitoring, and spectral analysis was carried out. LVM was measured by echocardiography according to Devereux and Reicheck's formula indexed for body height (m2.7) to account for obesity. Anthropometric variables, systolic, and diastolic blood pressure levels decreased in both groups of treatment without statisticall difference between them. Losartan increased heart rate variability (from 70.0 to 82.3 ms; P=0.01), and decreased low frequency–high frequency index (from 6.6 to 4.9; P=0.001), and LVM (from 49.2 to 45.2 g; P=0.004). In the multiple regression analysis for factors associated with reduction in LVM; treatment with losartan, and decrease in SBP were the only factors included in the model (R2=0.60; P=0.003). To conclude losartan, but not spironolactone, decreased LVM and heart sympathetic overactivity in prehypertensive obese subjects after 16 weeks of treatment. Regression on LVM was associated with reduction on SBP levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rumantir MS, Vaz M . Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17: 1125–1133.

    Article  CAS  Google Scholar 

  2. Karason K, Molgaard H, Wikstrand J, Sjostryom L . Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999; 83: 1242–1247.

    Article  CAS  Google Scholar 

  3. Amador N et al. Leptin and heart sympathetic activity in normotensive obese and non obese subjects. Ital Heart J 2004; 5: 29–35.

    PubMed  Google Scholar 

  4. Levy D et al. Prognostic implications of echocardiographic determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561–1566.

    Article  CAS  Google Scholar 

  5. Amador N et al. Relationship between left ventricular mass and heart sympathetic activity in male obese subjects. Arch Med Res 2004; 35: 54–58.

    Article  CAS  Google Scholar 

  6. Ferrannini E et al. Insulin. New roles for an ancient hormone. Eur J Clin Invest 1999; 29: 842–852.

    Article  CAS  Google Scholar 

  7. Carey RM, Siragy HM . Newly recognized components of the rennin–angiotensin system: potential roles and cardiovascular renal regulation. Endocr Rev 2003; 24: 261–271.

    Article  CAS  Google Scholar 

  8. Casolo G et al. Decreased spontaneous heart rate variability on congestive heart failure. Am J Cardiol 1989; 64: 1162–1167.

    Article  CAS  Google Scholar 

  9. De Ferrari GM, Vanoli E, Schwartz PJ . Cardiac vagal activity, myocardial ischemia and sudden death. In: Zipes DP, Jalife J (eds). Cardiac electrophysiology: From cell to bedside. WB Saunders Co.: Philadelphia, PA, 1995 pp 422–434.

    Google Scholar 

  10. Oparil S, Zaman AM, Calhoun DA . Pathogenesis of hypertension. Ann Intern Med 2003; 139: 761–776.

    Article  CAS  Google Scholar 

  11. McConnaughey MM, McConnaughey JS, Ingenito AJ . Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999; 39: 547–559.

    Article  CAS  Google Scholar 

  12. Chorbanian AV et al. for The National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  Google Scholar 

  13. Vasan RS et al. Assessment of frequency of progression to hypertension in non hypertensive participants in The Framingham Heart Study. Lancet 2001; 358: 1682–1686.

    Article  CAS  Google Scholar 

  14. Jackson AS, Pollock M . Practical assessment of body composition. Phys Sports Med 1985; 13: 76–90.

    Article  CAS  Google Scholar 

  15. Devereux RB, Lutas EM, Casale PN . Standardisation of M mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222–1230.

    Article  CAS  Google Scholar 

  16. Devereux RB, Reicheck N . Echocardiographic determination of left ventricular mass in man: anatomic validation of method. Circulation 1977; 55: 613–618.

    Article  CAS  Google Scholar 

  17. de Simone G et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol 1992; 20: 1251–1260.

    Article  CAS  Google Scholar 

  18. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043–1065.

    Article  Google Scholar 

  19. Haffner SM, Miettinem H, Stern MP . The homeostatic model in the San Antonio heart study. Diabetes Care 1997; 20: 1087–1092.

    Article  CAS  Google Scholar 

  20. Browner WS, Black D, Newman T, Hulley SB . Estimación del tamaño de la muestra y de la potencia. In: Hulley SB, Cummings SR (eds). Diseño de la investigación clínica. DOYMA: Barcelona, España, 1993 pp 153–165.

    Google Scholar 

  21. de Simone G et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056–1062.

    Article  CAS  Google Scholar 

  22. de Simone G et al on behalf of the MAVI Investigators. Prognosis of inappropriate left ventricular mass in hypertension: The MAVI study. Hypertension 2002; 40: 470–476.

    Article  CAS  Google Scholar 

  23. Messereli FH et al. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983; 74: 808–812.

    Article  Google Scholar 

  24. Sakata K et al. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 2002; 20: 103–110.

    Article  CAS  Google Scholar 

  25. Klein I et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425–430.

    Article  CAS  Google Scholar 

  26. Martina B, Dieterle T, Weinbacher M, Battegay E . Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92: 110–114.

    Article  CAS  Google Scholar 

  27. Kanno Y et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43: 380–386.

    Article  CAS  Google Scholar 

  28. Unger T, Azizi M, Belz GG . Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. J Hum Hypertens 2000; 14(Suppl 2): S23–S31.

    Article  CAS  Google Scholar 

  29. Glynn RJ et al. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105–110.

    Article  CAS  Google Scholar 

  30. Celentano A et al. Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens 2002; 20: 531–537.

    Article  CAS  Google Scholar 

  31. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzime inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study (RALES)). Am J Cardiol 1996; 78: 902–907.

  32. McGrath BP et al. Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1990; 16: 831–838.

    Article  CAS  Google Scholar 

  33. Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. Br J Clin Pharmacol 1984; 18: 51–56.

  34. Crandall DL, Herzlinger HE, Saunders BD . Developmental aspects of the adipose tissue renin-angiotensin system: therapeutic implicactions. Drug Dev Res 1994; 32: 117–125.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Fondo de Fomento a la Investigación (FOFOI) No. FP-2003/072. This trial was approved by the Local Ethical Committee No. 2003-181-02.

Author information

Authors and Affiliations

  1. Unidad de Investigación Epidemiológica, Instituto Mexicano del Seguro Social, Guanajuato, México

    N Amador, J M Guízar & M López

  2. Servicio de Cardiología, Hospital de Especialidades León Guanajuato, Instituto Mexicano del Seguro Social, Guanajuato, México

    J J Encarnación & L Rodríguez

Authors
  1. N Amador
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J J Encarnación
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J M Guízar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M López
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J M Guízar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amador, N., Encarnación, J., Guízar, J. et al. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. J Hum Hypertens 19, 277–283 (2005). https://doi.org/10.1038/sj.jhh.1001816

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001816

Keywords

This article is cited by

Search

Advanced search

Quick links